Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction ...
The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for ...
AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct. 15th. While investors will wait to hear about quarterly earnings on ...
AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi ...
AbbVie (NYSE: ABBV) continues to demonstrate its prowess in navigating the challenging landscape of drug development and ...
Throw in a generous dividend payout that has more than tripled from that 2013 stock split and you have a blue-chip stock with a lot to offer in AbbVie. Tobacco giant Altria is the bluest of the ...